Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Only the indication (acute treatment in adults) and non-prevention limitation are directly supported by the provided label excerpts. Most other claims (side effects, mechanism, specific symptom triage, dosing-frequency guidance, and safety considerations) are not supported by the supplied label text and some appear to go beyond what is explicitly provided.
Category Scores
Accurate Statements
Zembrace SymTouch is an injectable form of sumatriptan used to treat acute migraine attacks.
Supported for acute migraine treatment in adults: Section 1 INDICATIONS AND USAGE: “ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults.” (Label excerpt provided does not explicitly state “injectable form” or “acute migraine attacks” wording, but concept is aligned.)
Using sumatriptan too frequently can increase the risk of medication-overuse headache (rebound headache).
Supported: Section 5.6 Medication Overuse Headache: “Overuse of acute migraine drugs… may lead to exacerbation of headache (medication overuse headache).”
Medication-overuse headache occurs when headaches become more frequent instead of improving.
Partially supported by Section 5.6 wording about “exacerbation of headache (medication overuse headache)”; the provided label excerpt does not explicitly define it as “more frequent instead of improving.”
Unsupported Statements
Common side effects of Zembrace SymTouch relate to vasoconstriction and medication effects in the body.
No adverse reaction listing, mechanism, or “vasoconstriction” framing is included in the provided label excerpts.
Commonly reported side effects include tingling or numbness.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Commonly reported side effects include dizziness.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Commonly reported side effects include drowsiness.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Commonly reported side effects include feeling hot or flushed.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Some people report nausea or vomiting after dosing.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Some people report muscle weakness after dosing.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Some people report pain or tightness after dosing (including chest, throat, or jaw).
No specific adverse reaction symptoms are provided in the supplied label excerpts.
Side effects of Zembrace SymTouch can vary based on dose.
No dose-dependent adverse reaction statement is provided in the supplied label excerpts.
Side effects of Zembrace SymTouch can vary based on individual sensitivity.
No statement about variability by individual sensitivity is provided in the supplied label excerpts.
Side effects of Zembrace SymTouch can vary based on how many doses are used in a day.
The provided label excerpt only states medication overuse risk in general; it does not support dose-count-based side-effect variability claims.
Sumatriptan products can affect blood vessels and the heart.
No such statements are present in the provided label excerpts.
Urgent medical help is recommended for signs of heart or circulation problems such as chest pain/pressure.
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for signs of heart or circulation problems such as shortness of breath.
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for signs of heart or circulation problems such as fainting.
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for signs of heart or circulation problems such as severe dizziness.
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for symptoms suggesting stroke or blood-vessel problems (e.g., weakness on one side).
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for symptoms suggesting stroke or blood-vessel problems (e.g., trouble speaking).
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent medical help is recommended for symptoms suggesting stroke or blood-vessel problems (e.g., sudden vision changes).
No symptom-by-symptom triage guidance is included in the provided label excerpts.
Urgent care is recommended for severe allergic reactions such as swelling of the face/lips.
No allergic reaction symptom triage guidance is included in the provided label excerpts.
Urgent care is recommended for severe allergic reactions such as hives.
No allergic reaction symptom triage guidance is included in the provided label excerpts.
Urgent care is recommended for severe allergic reactions such as trouble breathing.
No allergic reaction symptom triage guidance is included in the provided label excerpts.
Some people experience tightness or pain in the chest, throat, or jaw after taking sumatriptan.
No specific adverse reaction symptoms are provided in the supplied label excerpts.
After injection, short-term effects are commonly reported around the time the medicine is working.
No timing statement about common effects is provided in the supplied label excerpts.
After injection, patients may notice tingling.
No specific adverse reaction symptom list is provided in the supplied label excerpts.
After injection, patients may notice flushing or heat.
No specific adverse reaction symptom list is provided in the supplied label excerpts.
After injection, patients may notice dizziness.
No specific adverse reaction symptom list is provided in the supplied label excerpts.
After injection, patients may notice drowsiness.
No specific adverse reaction symptom list is provided in the supplied label excerpts.
After injection, patients may notice a sensation of tightness.
No specific adverse reaction symptom list is provided in the supplied label excerpts.
Clinicians generally limit triptan use.
No label support for general clinician behavior is provided in the supplied label excerpts.
Clinicians generally encourage patients to talk through a safe maximum number of doses per day and per week.
The provided label excerpt provides a maximum cumulative dose in 24 hours and separation by at least 1 hour, but does not support general “per day and per week” counseling language.
Overuse raises the chance of dose-related side effects like dizziness.
No label excerpt supports a linkage between overuse and specific adverse reactions such as dizziness.
Overuse raises the chance of dose-related side effects like nausea.
No label excerpt supports a linkage between overuse and specific adverse reactions such as nausea.
Overuse raises the chance of dose-related side effects like cardiovascular symptoms.
The provided label excerpt only supports medication overuse headache; it does not support this specific linkage.
If sumatriptan (including Zembrace) is needed repeatedly, the prescriber may adjust the plan.
No label excerpt supports prescriber “adjust the plan” language for repeated use.
Extra caution is needed for people with known heart disease or risk factors.
No specific warning wording for these groups is included in the provided label excerpts.
Extra caution is needed for people with uncontrolled high blood pressure.
No specific warning wording for these groups is included in the provided label excerpts.
Extra caution is needed for people with prior stroke or TIA.
No specific warning wording for these groups is included in the provided label excerpts.
Extra caution is needed for people with significant circulation problems.
No specific warning wording for these groups is included in the provided label excerpts.
Extra caution is needed for people taking certain interacting medicines, for example other serotonergic drugs.
No drug interaction excerpt is provided in the supplied label excerpts.
These factors can increase the risk of serious adverse reactions.
While general risk language may exist elsewhere, the supplied excerpts do not explicitly support this summarizing statement tied to the listed factors.
Contradictions
Important Omissions
ZEMBRACE SymTouch dosing limits and administration route (3 mg subcutaneous; max 12 mg/24 hours; separate by at least 1 hour; do not administer by any other route).
Importance:
Moderate
Clear statement that ZEMBRACE SymTouch is not indicated for prevention of migraine attacks (Limitations of Use).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about adverse effects and urgency recommendations are not supported by the provided label excerpts, and some dosing/route details are omitted, which reduces alignment with on-label safety communication content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Large portion of side-effect, timing, and symptom-urgency/triage statements are unsupported by the supplied label excerpts; dosing route/maximum limits and the explicit “not for prevention” limitation are omitted.
Suggested Improvement
Restrict content to FDA label-supported points from the provided excerpts: acute adult indication; not for prevention; medication overuse headache concept; and include label dosing/administration limits (3 mg SC; max 12 mg/24h; ≥1 hour between doses; do not use other routes) when discussing dosing.